Quick Answer
Foghorn Therapeutics Inc. reported Cash and Equivalents of $80.88 million for fiscal year 2025.
Foghorn Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $80.88M | +45.8% |
| 2024 | $55.45M | -31.0% |
| 2023 | $80.34M | +53.9% |
| 2022 | $52.21M | -48.4% |
| 2021 | $101.14M | +9.0% |
| 2020 | $92.80M | +519.4% |
| 2019 | $14.98M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $89.33M | +54.9% | +23.1% |
| June 30, 2025 | $72.57M | -47.8% | +18.9% |
| March 31, 2025 | $61.03M | -23.0% | +10.0% |
| December 31, 2024 | $55.45M | -31.0% | -3.9% |
| September 30, 2024 | $57.68M | -18.0% | -58.5% |
| June 30, 2024 | $138.95M | +140.8% | +75.3% |
| March 31, 2024 | $79.25M | +56.5% | -1.3% |
| December 31, 2023 | $80.34M | +53.9% | +14.3% |
- Foghorn Therapeutics Inc. showed an increase of +45.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Foghorn Therapeutics Inc.’s cash and equivalents has grown by 439.9% (from $14.98 million to $80.88 million).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: